Expression and significance of annexin A2 in patients with viral community-acquired pneumonia

doi:10.3877/cma.j.issn.1674-6902.2022.02.004

Abstract

Abstract:

Objective

To investigate the expression of Annexin A2 in peripheral blood mononuclear cells of patients with viral community-acquired pneumonia, and provide new ideas for the antiviral treatment of viral pneumonia.

Methods

A total of 50 patients with viral CAP and 47 patients with bacterial CAP who were hospitalized in our hospital from January 2016 to January 2018 were selected as the virus group and bacteria group, respectively, and 48 healthy patients were selected as the control group. The quantitative real-time polymerase chain reaction (qPCR) method was used to determine the expression level of annexin A2 mRNA, and the western-blot method was used to detect the expression level of annexin A2 protein. Compare the relative expression levels of each group.

Results

There were 40 cases of single virus infection and 10 cases of mixed virus infection in the virus group. Influenza virus (30%) accounted for the highest proportion of single virus infections, followed by rhinoviruses and coronaviruses, and 7 mixed virus infections included influenza viruses. The expression of annexin A2 mRNA in the viral group and the bacterial group was higher than that in the control group, and the expression of the viral group was higher than that of the bacterial group. The difference was statistically significant (P<0.05). The expression of mRNA and protein of ANXA2 in the coronavirus group was higher than that of the bacterial CAP group and the control group. The difference was statistically significant (P<0.05).

Conclusion

ANXA2 may participate in the occurrence of viral CAP through more ways and mechanisms. The role of ANXA2 in coronavirus infection may be more significant. ANXA2 has the potential to become a target of antiviral therapy for viral CAP, especially coronavirus CAP.

Key words: Viral pneumonia, Coronavirus, Annexin A2

Yao Chen, Fuhui Chen. Expression and significance of annexin A2 in patients with viral community-acquired pneumonia[J]. Chinese Journal of Lung Diseases(Electronic Edition), 2022, 15(02): 157-160.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhfbjbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-6902.2022.02.004

https://zhfbjbzz.cma-cmc.com.cn/EN/Y2022/V15/I02/157

Figures/Tables 4

References 33

1	Lanks CW, Musani AI, Hsia DW. Community-acquired pneumonia and hospital-acquired pneumonia[J]. Med Clin North Am, 2019, 103(3): 487-501.
2	Burk M, El-Kersh K, Saad M, et al. Viral infection in community-acquired pneumonia: a systematic review and meta-analysis[J]. Eur Respir Rev, 2016, 25(140): 178-188.
3	Rider AC, Frazee BW. Community-acquired pneumonia[J]. Emerg Med Clin North Am, 2018, 36(4): 665-683.
4	Cavallazzi R, Ramirez JA. Influenza and viral pneumonia[J]. Clin Chest Med, 2018, 39(4): 703-721.
5	Jain S. Epidemiology of viral pneumonia[J]. Clin Chest Med, 2017, 38(1): 1-9.
6	Dandachi D, Rodriguez-Barradas MC. Viral pneumonia: etiologies and treatment[J]. J Investig Med, 2018, 66(6): 957-965.
7	窦　唱，李兴旺. 社区获得性病毒性肺炎病原学治疗研究进展[J]. 中国病毒病杂志，2018, 8(5): 421-426.
8	Bharadwaj A, Bydoun M, Holloway R, et al. Annexin A2 heterotetramer：structure and function[J]. Int J Mol Sci, 2013, 14(3): 6259-6305.
9	Dallacasagrande V, Hajjar KA. Annexin A2 in inflammation and host defense[J]. Cells, 2020, 9(6): 1499.
10	Schloer S, Pajonczyk D, Rescher U. Annexins in translational research：hidden treasures to be found[J]. Int J Mol Sci, 2018, 19(6): 1781.
11	Taylor JR, Skeate JG, Kast WM. Annexin A2 in virus infection[J]. Front Microbiol, 2018, 9: 2954.
12	LeBouder F, Morello E, Rimmelzwaan GF, et al. Annexin Ⅱ incorporated into influenza virus particles supports virus replication by converting plasminogen into plasmin [J]. J Virol, 2008, 82(14): 6820-6828.
13	LeBouder F, Lina B, Rimmelzwaan GF, et al. Plasminogen promotes influenza A virus replication through an annexin 2-dependent pathway in the absence of neuraminidase[J]. J Gen Virol, 2010, 91(Pt 11): 2753-2761.
14	Su H, Yang X, Wang S, et al. Effect of annexin Ⅱ-mediated conversion of plasmin from plasminogen on airborne transmission of H9N2 avian influenza virus[J]. Vet Microbiol, 2018, 223: 100-106.
15	Ma Y, Sun J, Gu L, et al. Annexin A2 (ANXA2) interacts with nonstructural protein 1 and promotes the replication of highly pathogenic H5N1 avian influenza virus[J]. BMC Microbiol, 2017, 17(1): 191.
16	Fang YT, Lin CF, Liao PC, et al. Annexin A2 on lung epithelial cell surface is recognized by severe acute respiratory syndrome-associated coronavirus spike domain 2 antibodies[J]. Mol Immunol, 2010, 47(5): 1000-1009.
17	Malhotra R, Ward M, Bright H, et al. Isolation and characterisation of potential respiratory syncytial virus receptor(s) on epithelial cells[J]. Microbes Infect, 2003, 5(2): 123-133.
18	Derry MC, Sutherland MR, Restall CM, et al. Annexin 2-mediated enhancement of cytomegalovirus infection opposes inhibition by annexin 1 or annexin 5[J]. J Gen Virol, 2007, 88(Pt 1): 19-27.
19	Koga R, Kubota M, Hashiguchi T, et al. Annexin A2 Mediates the localization of measles virus matrix protein at the plasma membrane[J]. J Virol, 2018, 92(10): e00181-18.
20	Heyraud S, Jaquinod M, Durmort C, et al. Contribution of annexin 2 to the architecture of mature endothelial adherens junctions[J]. Mol Cell Biol, 2008, 28(5): 1657-1668.
21	Luo M, Flood EC, Almeida D, et al. Annexin A2 supports pulmonary microvascular integrity by linking vascular endothelial cadherin and protein tyrosine phosphatases[J]. J Exp Med, 2017, 214(9): 2535-2545.
22	Swisher JF, Khatri U, Feldman GM. Annexin A2 is a soluble mediator of macrophage activation[J]. J Leukoc Bio, 2007, 82(5): 1174-1184.
23	Song C, Zhou X, Dong Q, et al. Regulation of inflammatory response in human chondrocytes by lentiviral mediated RNA interference against S100A10[J]. Inflamm Res, 2012, 61(11): 1219-1227.
24	Laumonnier Y, Syrovets T, Burysek L, et al. Identification of the annexin A2 heterotetramer as a receptor for the plasmin-induced signaling in human peripheral monocytes[J]. Blood, 2006, 107(8): 3342-3349.
25	Li Q, Ke F, Zhang W, et al. A role for the annexin A2 amino-terminal peptide in the plasmin-induced activation of human peripheral monocytes[J]. Mol Immunol, 2010, 47(14): 2405-2410.
26	Li Q, Laumonnier Y, Syrovets T, et al. Plasmin triggers cytokine induction in human monocyte-derived macrophages[J]. Arterioscler Thromb Vasc Biol, 2007, 27(6): 1383-1389.
27	Swisher JF, Burton N, Bacot SM, et al. Annexin A2 tetramer activates human and murine macrophages through TLR4[J]. Blood, 2010, 115(3): 549-558.
28	Zhang S, Yu M, Guo Q, et al. Annexin A2 binds to endosomes and negatively regulates TLR4-triggered inflammatory responses via the TRAM-TRIF pathway[J]. Sci Rep, 2015, 5: 15859.
29	瞿介明，曹　彬. 中国成人社区获得性肺炎诊断和治疗指南(2016年版)[J]. 中华结核和呼吸杂志，2016, 39(4): 253-279.
30	何丽艳. 54例社区获得性肺炎病原学分析[D]. 中国医科大学，2018: 23-45.
31	刘馨玉，李　萌，陈明伟，等. 成人社区获得性肺炎住院患者的病原学分析[J]. 临床医学研究与实践，2019, 4(29): 20-21.
32	陈　静，李晓光，王　伟，等. 成人社区获得性肺炎病原学特点分析[J]. 中华急诊医学杂志，2020, 29(9): 1210-1213.
33	刘　熙，李　琦. 我国成人社区获得性肺炎诊疗现状及思考[J/CD]. 中华肺部疾病杂志(电子版), 2021, 14(3): 387-389.

基因名	上游引物序列(5′-3′)	下游引物序列(5′-3′)
ANXA2	TCTCTATGACGCTGGAGTGAAG	AACCTCTTTCCTGATGCTTTC
β-actin	GGCACCCAGCACAATGAA	GGAAGGTGGACAGCGAGG

基因名	上游引物序列(5′-3′)	下游引物序列(5′-3′)
ANXA2	TCTCTATGACGCTGGAGTGAAG	AACCTCTTTCCTGATGCTTTC
β-actin	GGCACCCAGCACAATGAA	GGAAGGTGGACAGCGAGG

病原体结果	例数	病原体结果	例数
甲型流感病毒	12	人副流感病毒	1
鼻病毒	9	冠状病毒+甲型流感病毒	3
冠状病毒	8	鼻病毒+人副流感病毒	2
乙型流感病毒	3	鼻病毒+腺病毒	1
腺病毒	2	乙型流感病毒+甲型流感病毒	1
人偏肺病毒	2	甲型流感病毒+肠道病毒	1
呼吸道合胞病毒	2	甲型流感病毒+鼻病毒	1
肠道病毒	1	鼻病毒+甲型流感病毒+冠状病毒	1

病原体结果	例数	病原体结果	例数
甲型流感病毒	12	人副流感病毒	1
鼻病毒	9	冠状病毒+甲型流感病毒	3
冠状病毒	8	鼻病毒+人副流感病毒	2
乙型流感病毒	3	鼻病毒+腺病毒	1
腺病毒	2	乙型流感病毒+甲型流感病毒	1
人偏肺病毒	2	甲型流感病毒+肠道病毒	1
呼吸道合胞病毒	2	甲型流感病毒+鼻病毒	1
肠道病毒	1	鼻病毒+甲型流感病毒+冠状病毒	1

[1]	Lingjie Wu, Ruilie Chen, Guijia Chen, Xiangming Xiao, Zhongbin Lin. Antiviral treatment of two cases with human immunodeficiency virus complicated with severe acute respiratory syndrome coronavirus 2 co-infection and literatures review [J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2023, 17(04): 282-286.
[2]	Cailing Chen, Jinfeng Ji, Yuhong Wang, Jing Xu, Xiangan Zhu, Wei Li, Xiyan Hao, Aiqin Li. Integrated treatment management and countermeasures of emergency abdominal multiple injuries during COVID-19 epidemic prevention and control [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2022, 16(05): 560-563.
[3]	Hongmin Wang, Yunbo Xie, Yanhu Wang, Fusheng Wang. The advance of clinical research in mesenchymal stem cell treatment for COVID-19 [J]. Chinese Journal of Cell and Stem Cell(Electronic Edition), 2023, 13(04): 247-256.
[4]	Xue Tian, Hui Xie, Ruilan Wang. Research progress in acute respiratory distress syndrome related pulmonary fibrosis [J]. Chinese Journal of Critical Care & Intensive Care Medicine(Electronic Edition), 2024, 10(03): 258-264.
[5]	Jibin Gong, Guangfeng Liu, Bao Liu, Meichen Yan, Mingmin Pang, Yue Xu, Tingyu Meng, Nana Xu, Shaohua Fan, Hao Wang. Research progress of viral pneumonia complicated with invasive pulmonary aspergillosis [J]. Chinese Journal of Critical Care & Intensive Care Medicine(Electronic Edition), 2023, 09(04): 385-390.
[6]	Ling Liu, Huiying Zhao, Xuyan Li, Yuan Cheng, Qiaoxia Luo, Yun Yu, Yi Yang, Haibo Qiu. Bedside monitoring of spontaneous respiratory effort in patients with COVID-19 [J]. Chinese Journal of Critical Care & Intensive Care Medicine(Electronic Edition), 2022, 08(04): 367-370.
[7]	Shuyuan Qian, Xiaoqing Li, Yingzi Huang, Yi Yang, Chun Pan, Haibo Qiu. Therapy strategies for elderly critically ill patients with novel coronavirus pneumonia [J]. Chinese Journal of Critical Care & Intensive Care Medicine(Electronic Edition), 2022, 08(03): 267-271.
[8]	Xiaoyan Wu, Zhixiang Yang, Jiangquan Yu, Ruiqiang Zheng. Evaluation of the clinical characteristics and the prone position ventilation effects in elderly patients with novel coronavirus (COVID-19) pneumonia in Yangzhou area [J]. Chinese Journal of Critical Care & Intensive Care Medicine(Electronic Edition), 2022, 08(03): 216-222.
[9]	Lu Ma, Songqiao Liu, Yan Kang, Zhixiong Wu, Xiaoqing Li, Cuirong Xu. Intensive care for elderly patients with COVID-19: prevention of progression to critically ill [J]. Chinese Journal of Critical Care & Intensive Care Medicine(Electronic Edition), 2022, 08(03): 211-215.
[10]	Songqiao Liu, Shengyun Wang, Zhixiong Wu, Lu Ma, Xiaochun Ma, Xiangdong Guan, Yi Yang. The post-COVID-19 era: tremendous challenges of underlying comorbidities [J]. Chinese Journal of Critical Care & Intensive Care Medicine(Electronic Edition), 2022, 08(03): 207-210.
[11]	Wenpeng Huang, Jie Liu, Liming Li, Jiameng Hou, Jianbo Gao. Application value of dual-source dual-energy computed tomography in 2019 novel coronavirus pneumonia [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2022, 12(04): 198-203.
[12]	Bo Yu, Fang Wang. Summary of nucleic acid testing experience in Yunnan Cardiovascular Hospital under the background of COVID-19 normalization [J]. Chinese Journal of Clinical Laboratory Management(Electronic Edition), 2022, 10(03): 170-174.
[13]	Yiming Qi, Wenzhi Pan, Fengqin Zhu, Daxin Zhou, Junbo Ge. Safety analysis of 19 cases of transcatheter aortic valve replacement after COVID-19 infection [J]. Chinese Journal of Heart and Heart Rhythm(Electronic Edition), 2023, 11(02): 105-108.
[14]	Jiangtao Yin, Yuchao Wang, Xin Pin, Zhilong Miao, Qiong Mei, Ziqiang Huang, Dadong Liu. Correlation betweenhypokalemia and clinical prognosis in patients with COVID-19 infection [J]. Chinese Journal of Hygiene Rescue(Electronic Edition), 2023, 09(02): 70-79.
[15]	Danyang Tian, Xiaoxuan Liu, Shan Ye, Xinran Ma, Dongsheng Fan, Yu Fu. The impact of COVID-19 on the standardized training of neurology residents [J]. Chinese Journal of Cerebrovascular Diseases(Electronic Edition), 2023, 17(05): 499-504.

Please choose a citation manager

Content to export